Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?

Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?

Authors

  • Giulia Calabrese Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Gaetano Licata Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Alessio Gambardella Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Alina De Rosa Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Roberto Alfano Department of Anesthesiology Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy
  • Giuseppe Argenziano Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

Keywords:

atopic dermatitis, treatments, therapy, topicals, systemic therapy

Abstract

Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional drugs remain a milestone for the treatment of this dermatosis. Dermatologists need a good knowledge of all therapies for an integrated and personalized management of patients.

References

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. DOI: 10.1016/S0140-6736(17)31191-1. PMID: 28478972.

Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328-1336. DOI: 10.1016/j.jaad.2020.02.060. PMID: 32135208.

Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45. DOI: 10.1016/j.jaad.2020.03.049. PMID: 32229281.

Ribero S, Giura MT, Viola R, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. J Eur Acad Dermatol Venereol. 2020;34(8):e380-e383. DOI: 10.1111/jdv.16219. PMID: 31960496.

.Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32. DOI: 10.1016/j.jaad.2014.03.023. PMID: 24813302. PMCID: PMC4326095.

Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17 Suppl 1:49-56. DOI: 10.1111/j.1396-0296.2004.04s1006.x. PMID: 14728699.

Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009;8(1):40-43. DOI: 10.1111/j.1473-2165.2009.00422.x. PMID: 19250165.

Dabade TS, Davis DM, Wetter DA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100-6. DOI: 10.1016/j.jaad.2011.06.025. PMID: 21978575.

Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579-585. DOI: 10.1111/j.1365-2133.2006.07157.x. PMID: 16536797.

Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. DOI: 10.1016/j.jaad.2014.03.030. PMID: 24813298. PMCID: PMC4410179.

Nolan K, Marmur E. Moisturizers: reality and the skin benefits. Dermatol Ther. 2012;25(3):229-233. DOI: 10.1111/j.1529-8019.2012.01504.x. PMID: 22913439.

Furuhashi T, Oda T, Torii K, Nishida E, Morita A. Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis. J Dermatol. 2021;48(2):e74-e75. DOI: 10.1111/1346-8138.15638. PMID: 33035368; PMCID: PMC7891664.

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. DOI: 10.1016/S0140-6736(17)31191-1. PMID: 28478972.

Treister AD, Kraff-Cooper C, Lio PA. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol. 2018;154(10):1208‐1211. DOI: 10.1001/jamadermatol.2018.2690. PMID: 30167653. PMCID: PMC6233741.

Calabrese G, Gambardella A, Licata G, Di Brizzi EV, Alfano R, Argenziano G. Dupilumab and conjunctivitis: a case series of twenty patients. J Eur Acad Dermatol Venereol. 2021;35(9):e612-e614. DOI: 10.1111/jdv.17210. PMID: 33657247.

Jaros J, Hendricks AJ, Shi VY, Lio PA. A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis. Dermatitis. 2020;31(3):169-177. DOI: 10.1097/DER.0000000000000590. PMID: 32355092.

Gori N, Chiricozzi A, Malvaso D, et al. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. Dermatology. 2021;237(4):535-541. DOI: 10.1159/000512890. PMID: 33477153.

Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006; 367:839–846. DOI: 10.1016/S0140-6736(06)68340-2. PMID: 16530578.

Downloads

Published

2022-02-02

Issue

Section

Review

How to Cite

1.
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?. Dermatol Pract Concept [Internet]. 2022 Feb. 2 [cited 2024 Apr. 23];12(1):e2022155. Available from: https://dpcj.org/index.php/dpc/article/view/2310

Share